Modern photodynamic therapy (PDT) demands next-generation photosensitizers (PSs) that overcome heavy-atom dependency and enhance efficacy beyond traditional, highly oxygen-dependent type II mechanisms. We introduce herein TCI-NH, as a thiochromenocarbazole imide derivative designed for type I photodynamic action. Upon light activation, TCI-NH efficiently favors superoxide (O2•-) and PS-centered radical formation instead of singlet oxygen (1O2) generation. Its high luminescence efficiency and selective localization in both the endoplasmic reticulum and mitochondria enable precise, image-guided PDT. Notably, interactions with biomolecules, such as serum albumin or DNA, enhance TCI-NH's emission by up to 40-fold and amplify radical generation by up to 5-fold. With negligible dark toxicity, this results in ∼120 nM photocytotoxicity along with an impressive phototherapeutic index exceeding 200. Real-time live-cell imaging revealed rapid, light-triggered cytotoxicity characterized by apoptotic body formation and extensive cellular damage. With its small size, heavy-atom-free structure, exceptional, organelle specificity, and therapeutic efficacy, TCI-NH sets a new benchmark for anticancer type I PDT.
16 April 2025 in ACS Pharmacology & Translational Science
Rhabdomyosarcoma is a highly aggressive soft tissue cancer that predominantly affects children and adolescents. Current treatment outcomes are poor, highlighting the urgent need for potent therapeutic alternatives. Preclinical research on photodynamic therapy (PDT) continues to gain attention as a promising and minimally invasive treatment strategy. Recently, PDT using the heavy-atom-free photosensitizer dibenzothioxanthene imide (DBI), which targets cancer-associated G-quadruplex (G4) DNA, has demonstrated high efficacy at nanomolar concentrations. In here, transgenic zebrafish with rhabdomyosarcoma tumors were utilized to evaluate the therapeutic potential of DBI treatment. We demonstrate that photoactivated DBI efficiently induce localized tumor necrosis, resulting in significant rhabdomyosarcoma regression compared to untreated controls. In fact, in comparison to the healthy cells surrounding the tumor, a high level of G4s was detected, as visualized by a G4-specific antibody. Notably, muscle and nerve cells within the treated tumor area were particularly affected, further underscoring its potency. These findings position DBI as a promising candidate for PDT in the treatment of rhabdomyosarcoma, offering selective G4-targeting capabilities and delivering robust therapeutic outcomes in in vivo models.
Two synthetic organic dyes of the Benzothioxanthene imide (BTI) family are explored as a promising electroactive material for organic light‐emitting electrochemical cells (LECs). The high thermal stability and ease of thin film processing make BTI‐based compounds suitable for these devices. However, their planar π‐conjugated structure often leads to aggregation‐caused quenching (ACQ), reducing luminescence in the solid state. To overcome this, this study has taken advantage of host‐guest interactions with 4,4′‐bis(9H‐carbazol‐9‐yl) biphenyl (p‐CBP), poly(9‐vinylcarbazole) (PVK), and poly(dioctylfluorene) (PFO) to suppress ACQ. The use of p‐CBP improved the internal electrical double layer (EDL) alignment within the film, resulting in higher luminescence compared to PFO and PVK‐based LECs. The BTI‐F dye, when incorporated into a dual host system with p‐CBP and PFO, achieved an impressive luminescence of up to 3900 cd m−2. Additionally, PFO enhanced charge balance, contributing to a blue shift in maximum absorption wavelength and increasing the device's tolerance. A triple‐host system (p‐CBP, PVK, PFO) further extended the device's half‐life (t1/2) to 54 min, demonstrating the potential of these host‐guest systems in advancing metal‐free LEC technology.